Frontline BioVentures is a Shanghai-based venture capital firm founded in 2012 that specializes in investing in innovative life science and healthcare companies across stages from early growth to later rounds. The firm deploys capital into biotechnology, medical technology, healthtech and related sectors with a focus on supporting scientific innovation and commercial development within China’s life sciences ecosystem and select global opportunities. It has managed multiple funds denominated in RMB and USD and participated in financings alongside industry partners and co-investors. Frontline’s investment activities span portfolio companies developing therapeutics, diagnostics and platform technologies with some achieving public listings or strategic acquisitions. The firm’s leadership draws on life science investment experience to guide portfolio growth and commercialization efforts.